Nursing Elites

1. A female patient is concerned about the side effects of hormone replacement therapy (HRT). What common side effect should the nurse explain?

• A. Weight gain
• B. Hair loss
• C. Increased libido
• D. Decreased energy levels

Correct answer: A

Rationale: The correct answer is A: Weight gain. Weight gain is a common side effect of hormone replacement therapy (HRT) due to hormonal changes. Patients should be informed about this possibility as part of their treatment plan. Hair loss (Choice B) is not a common side effect of HRT. Increased libido (Choice C) and decreased energy levels (Choice D) are not typically associated with HRT side effects. Therefore, the nurse should focus on discussing weight gain with the patient.

2. A patient is being educated on the administration of tinidazole (Tindamax). Which of the following indicates that the patient understands the administration of tinidazole?

• A. “I will report to the doctor if I have a slow heart rate.”
• B. “The medicine will leave a bitter or metallic taste in my mouth.”
• C. “I will report urinary urgency and incontinence.”
• D. “The medication is given in two doses every day.”

Correct answer: B

Rationale: The correct answer is B. Tinidazole (Tindamax) is known to cause a bitter or metallic taste in the mouth. This side effect is common and indicates that the patient understands the medication they are taking. Choices A, C, and D are incorrect because they do not specifically relate to the common side effects or administration details of tinidazole.

3. Which statement best conveys an aspect of the role of cerebrospinal fluid (CSF)?

• A. CSF provides immune protection to the brain and spinal cord by serving as a physical barrier.
• B. CSF cushions the brain and spinal cord, protecting them from injury.
• C. CSF plays a limited role in the exchange of nutrients and waste products between the blood and brain.
• D. CSF functions primarily as a medium for the transmission of nerve impulses.

Correct answer: B

Rationale: The correct answer is B. Cerebrospinal fluid primarily cushions the brain and spinal cord, protecting them from injury. Choice A is incorrect because while CSF contributes to the brain's immune environment, its main role is not providing immune protection as a physical barrier. Choice C is incorrect because CSF has a significant role in the exchange of nutrients and waste products, rather than a limited one. Choice D is incorrect as CSF is not primarily a medium for nerve impulse transmission, but rather serves as a protective and supportive fluid.

4. A male patient is receiving androgen therapy for hypogonadism. What adverse effect should the nurse monitor for during this therapy?

• A. Increased risk of bone fractures
• B. Increased risk of cardiovascular events
• C. Increased risk of liver dysfunction
• D. Increased risk of prostate cancer

Correct answer: B

Rationale: The correct answer is B: Increased risk of cardiovascular events. Androgen therapy can lead to an increased risk of cardiovascular events like heart attacks and strokes, especially in older patients. Monitoring for signs and symptoms of cardiovascular issues is essential during this therapy. Choices A, C, and D are incorrect because androgen therapy is not typically associated with an increased risk of bone fractures, liver dysfunction, or prostate cancer.

5. A hospital patient's complex medical history includes a recent diagnosis of kidney cancer. Which of the following medications is used to treat metastatic kidney cancer?

• A. Filgrastim (Neupogen)
• B. Aldesleukin (Proleukin)
• C. Interferon alfa-2b (Intron A)
• D. Darbepoetin alfa (Aranesp)

Correct answer: B

Rationale: The correct answer is B: Aldesleukin (Proleukin). Aldesleukin is a medication used in the treatment of metastatic kidney cancer. It is a recombinant interleukin-2 that works by stimulating the immune system to attack cancer cells. Choice A, Filgrastim, is a medication used to stimulate the production of white blood cells. Choice C, Interferon alfa-2b, is used in the treatment of certain cancers but not specifically metastatic kidney cancer. Choice D, Darbepoetin alfa, is used to treat anemia by stimulating red blood cell production and is not indicated for metastatic kidney cancer.

Similar Questions